Evidence map›Paper›PMID 38602109›Full record

ArticleNeuropsychopharmacology reports2024

Can calcitonin gene-related peptide monoclonal antibodies ameliorate writer's cramp and migraine?

Keisuke Suzuki, Shiho Suzuki, Hiroaki Fujita, Hirotaka Sakuramoto, Mukuto Shioda, Koichi Hirata

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuropsychopharmacology reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Keisuke SuzukiDepartment of Neurology, Dokkyo Medical University, Mibu, Japan.ORCID https://orcid.org/0000-0003-0320-8993
Shiho SuzukiDepartment of Neurology, Dokkyo Medical University, Mibu, Japan.
Hiroaki FujitaDepartment of Neurology, Dokkyo Medical University, Mibu, Japan.
Hirotaka SakuramotoDepartment of Neurology, Dokkyo Medical University, Mibu, Japan.
Mukuto ShiodaDepartment of Neurology, Dokkyo Medical University, Mibu, Japan.
Koichi HirataDepartment of Neurology, Dokkyo Medical University, Mibu, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recently, calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) have become available as a prophylactic treatment for migraine and have shown high efficacy and safety in clinical practice. CGRP mAbs have been reported to be effective not only for migraine but also for other comorbidities, such as psychiatric complications in patients with migraine. However, there are no reports examining the effect of CGRP mAbs on dystonia. We treated a patient with comorbid migraine and focal task-specific dystonia (writer's cramp) with a CGRP mAb (erenumab) because of an increase in monthly migraine days despite the addition of migraine prophylaxis. In this patient, erenumab treatment for 3 months led to improvements in symptoms of both focal dystonia and migraine, suggesting a role for CGRP in the pathophysiology of both conditions.

Indexed as

Antibodies, Monoclonal, HumanizedCalcitonin Gene-Related PeptideDystonic DisordersMigraine DisordersAdultAntibodies, MonoclonalCalcitonin Gene-Related Peptide Receptor AntagonistsFemaleHumansMaleMiddle AgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedCalcitonin Gene-Related PeptideCalcitonin Gene-Related Peptide Receptor Antagonistserenumabcalcitonin gene‐related peptidefocal task‐specific dystoniamigraine

Identifiers

PMID38602109
PMCPMC11144594

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.